<DOC>
	<DOCNO>NCT02272634</DOCNO>
	<brief_summary>This Phase 2a , proof-of-concept , multicenter , randomize , double-blind , double dummy , 3-treatment , parallel study , low high YPL 001 dos ( low dose high dose twice daily [ BID ] ) placebo control moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) patient .</brief_summary>
	<brief_title>A Phase 2a Study Assess Safety , Daily Symptoms , Pharmacokinetics ( PK ) , Biomarkers YPL-001 Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Adult male and/or female , 40 80 year age ( inclusive ) . History COPD least 12 month prior screen . Diagnosed COPD define American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) guideline symptom compatible COPD least 12 month prior screen . Classified moderate severe COPD base current severity classification GOLD Stage 23 disease term postbronchodilator spirometry screen etc . History lifethreatening COPD include respiratory arrest , intensive care unit admission and/or require intubation . History 2 hospitalization COPD within 12 month prior screen . Presentation acute exacerbation COPD associate increase sputum volume change sputum color within 4 week Day 1 Runin Period . Evidence pulmonary heart disease , clinically significant pulmonary hypertension . etc .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>